Gleave ME - Search Results

1

Khalaf DJ, Sunderland K, Eigl BJ, Kollmannsberger CK, Ivanov N, Finch DL, Oja C, Vergidis J, Zulfiqar M, Gleave ME, Chi KN. Khalaf DJ, et al. Among authors: gleave me. Eur Urol. 2019 Jun;75(6):940-947. doi: 10.1016/j.eururo.2018.12.015. Epub 2018 Dec 24. Eur Urol. 2019. PMID: 30591354 Clinical Trial.

2

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.

Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Gleave ME, et al. J Urol. 1996 Jan;155(1):213-9. J Urol. 1996. PMID: 7490838 Clinical Trial.

3

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.

Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Goldenberg SL, et al. Among authors: gleave me. Urology. 1995 May;45(5):839-44; discussion 844-5. doi: 10.1016/s0090-4295(99)80092-2. Urology. 1995. PMID: 7538246 Clinical Trial.

4

Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer.

Gleave ME, Coupland D, Drachenberg D, Cohen L, Kwong S, Goldenberg SL, Sullivan LD. Gleave ME, et al. Urology. 1996 May;47(5):708-12. doi: 10.1016/s0090-4295(96)80016-1. Urology. 1996. PMID: 8650870

5

Low-dose cyproterone acetate plus mini-dose diethylstilbestrol--a protocol for reversible medical castration.

Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD. Goldenberg SL, et al. Among authors: gleave me. Urology. 1996 Jun;47(6):882-4. doi: 10.1016/S0090-4295(96)00048-9. Urology. 1996. PMID: 8677581 Clinical Trial.

6

Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model.

Gleave ME, Sato N, Goldenberg SL, Stothers L, Bruchovsky N, Sullivan LD. Gleave ME, et al. J Urol. 1997 May;157(5):1727-30. J Urol. 1997. PMID: 9112514

7

Transurethral electrovaporization of the prostate versus transurethral prostatic resection: a comparison of postoperative hemorrhage.

Chow VD, Sullivan LD, Wright JE, Goldenberg SL, Fenster HN, Gleave ME, McLoughlin MG. Chow VD, et al. Among authors: gleave me. Urology. 1998 Feb;51(2):251-3. doi: 10.1016/s0090-4295(97)00615-8. Urology. 1998. PMID: 9495706

8

Intermittent androgen suppression for prostate cancer: rationale and clinical experience.

Gleave M, Bruchovsky N, Goldenberg SL, Rennie P. Gleave M, et al. Eur Urol. 1998;34 Suppl 3:37-41. doi: 10.1159/000052297. Eur Urol. 1998. PMID: 9854195 Review.

9

Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.

Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A. Gleave ME, et al. Urology. 1999 Dec;54(6A Suppl):36-46. doi: 10.1016/s0090-4295(99)00453-7. Urology. 1999. PMID: 10606283

10

Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.

Miyake H, Chi KN, Gleave ME. Miyake H, et al. Among authors: gleave me. Clin Cancer Res. 2000 May;6(5):1655-63. Clin Cancer Res. 2000. PMID: 10815883

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

664 results

Search Page

Filters